Pfizer withdraws sickle-cell disease treatment | Reuters
WEB5 days ago · Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks ...
Pfizer pulls sickle cell drug oxbryta, raising safety concerns
WEB1 day ago · Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community. Concerns over its safety, flagged by European regulators, led to its removal just five years after approval. Doctors and patients now face uncertainty as the sudden discontinuation poses risks, including severe anemia.
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB6 days ago · Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
Pfizer withdraws sickle cell treatment due to safety concerns
WEB4 days ago · Pfizer has voluntarily withdrawn its sickle cell disease treatment Oxbryta (voxelotor) from the market due to safety concerns. The Food and Drug Administration (FDA) recommends clinicians stop prescribing the treatment and patients talk to their doctor about starting a different treatment. “I am disappointed as many other providers, patients …
Pfizer Recalls All of Its Sickle Cell Disease Treatment Over Safety ...
WEB4 days ago · Pfizer (PFE) shares declined Thursday after the drug maker recalled all lots of its sickle cell disease medicine worldwide because of concerns it could lead to severe pain and possibly death in ...
Pfizer withdraws sickle cell disease treatment on risk of …
WEB5 days ago · (Reuters) -U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication...
Pfizer pulls sickle cell disease therapy Oxbryta from markets
WEB5 days ago · Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago.
Pfizer Sickle Cell Drug Suspended by Europe in New Setback
WEB5 days ago · Oxbryta later received approval in Europe. When Pfizer acquired Global Blood Therapeutics in 2022, it said that Oxbryta and other sickle cell drugs under development could lead to more than $3 ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease
WEB5 days ago · NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time ...
EU Regulator Recommends Suspension of Pfizer's Sickle Cell ... - U.S. News
WEB5 days ago · REUTERS/Dado Ruvic/Illustration/File Photo. (Reuters) - The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's sickle cell disease drug Oxbryta on ...